iPhone Competition
advanced search

Welcome: Guest

log in

Dental Caries

Publication Date March 2008
Publisher Life Science Analytics
Product Type Report
Pages 28
ISBN Number not applicable
Product Code LSA02328
Price

£800.00
approximately: $1,572 | €1,017

PDF Buy Now
PRINT £850 ($1,670 | €1,080) Buy Now
Order above formats by FAX Order by FAX

Summary

Life Science Analytics', Central Nervous System Neuropathy contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
  • Keep track of your competitors and partners by better understanding their product pipeline.
  • Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
  • Maintain a critical competitive advantage.

Content

  • Recent Highlights and Changes
    • Neuropathy Pipeline Overview
      • % of Projects (by Phase of Development)
      • No. of Projects by Phase of Development
      • Marketed Products vs. Pipeline Products
    • Company Overview - Pipeline Projects
      • Company Overview - Pipeline Projects
      • Top Companies in late stage Neuropathy Projects
      • Chiesi Farmaceutici S.p.A
      • Anesiva, Inc.
      • Eisai Co Ltd
      • DARA BioSciences, Inc.
      • GlaxoSmithKline plc
      • Eli Lilly & Co
      • King Pharmaceuticals Inc
      • Glenmark Pharmaceuticals Limited
      • Nycomed
      • Nutra Pharma Corp
      • Pfizer Inc
      • Otsuka Pharmaceutical Co., Ltd.
      • ReceptoPharm, Inc
      • Pierre Fabre Medicament
      • Santhera Pharmaceuticals AG
      • Sanochemia Pharmazeutika AG
      • Talecris Biotherapeutics
      • Shionogi & Co., Ltd.
      • Vernalis Plc ADR
      • UCB S.A.
      • Top Companies in early stage Neuropathy Projects
      • Allon Therapeutics Inc.
      • Aegera Therapeutics Inc.
      • Cara Therapeutics Inc
      • Argolyn Bioscience Inc.
      • Krenitsky Pharmaceuticals Inc.
      • Daewoong Pharmaceutical Co. Ltd.
      • Neuren Pharmaceuticals Limited
      • Metabolic Pharmaceuticals Ltd.
      • Neuromed Pharmaceuticals Ltd.
      • erly NeuroMed Technologies)
      • NeuroDiscovery Ltd
      • NsGene A/S
      • Novasite Pharmaceuticals, Inc.
      • PharmAust Limited
      • Nyxis Neurotherapies, Inc.
      • SK Bio-Pharmaceuticals
      • Roxro Pharma Inc.
      • TheraQuest Biosciences
      • Sosei Group Corporation
      • VistaGen Therapeutics, Inc.
      • Trophos SA
    • Full Pipeline View
      • Pre Clinical Pipeline View
      • Phase I Pipeline View
      • Phase II Pipeline View
      • Phase III Pipeline View
      • on the Market Pipeline View
      • Discovery/Development Pipeline View
About this Product
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.

Ask a question about this product?

Recently Viewed Products
Dental Caries

Industry Events

Next Generation Protein Therapeutics

09 Sep 08 to 11 Sep 08
Budapest , Hungary
view summary >>

Impurities 2008

22 Sep 08 to 24 Sep 08
Prague, Czech Republic
view summary >>

#